MFN pricing is here, expanding, and increasingly complex. CMS is advancing multiple Innovation Center models that tie U.S. drug prices to international benchmarks across Medicaid and Medicare with implications for rebates, strategy, and market access.

This year brought major disruption to Medicaid and drug pricing policy, reshaping the environment for pharmaceutical manufacturers. This recap highlights the biggest changes and lays out what to expect in 2026.

When we started in 2005, our goal was simple: to bring clarity and insight to a complex and ever-changing system. Two decades later, that mission still drives everything we do.

Petauri, a leading purpose-built pharmaceutical services platform, announced today the acquisition of Artia Solutions, a premier consultancy specializing in Medicaid market access and the related dynamic regulatory environment.

HR 1 (2025) is the most significant law affecting Medicare, Medicaid, CHIP, and the ACA marketplace in over a decade. This Summary of the new law, and potential direct and indirect effects on the industry are provided for each provision contained in the law. The Summary also provides an initial assessment on how states will react to the far-ranging policy provisions.

In this look back at the events of 2024, we recap significant events that shaped Medicaid pharmacy practice.